Samsung Bioepis Co., Ltd. today announced the launch of OBODENCEtm (60 mg pre-filled syringe) and XBRYKtm (120 mg vial), denosumab biosimilars referencing Prolia and Xgeva. The products will be ...

A study of data from seven outpatient facilities in the New York region found that 20–24% of all the breast cancers diagnosed ...

Younger women face a persistent, underestimated breast cancer risk that demands earlier and more tailored screening.

Research has linked atrazine to various cancer types in agricultural workers, such as non-Hodgkin lymphoma and prostate cancer. Studies have also confirmed the herbicide to be an endocrine disruptor, ...

A study of data from seven outpatient facilities in the New York region found that 20-24% of all the breast cancers diagnosed during an 11-year period were found in women age 18 to 49, according to ...

Carpets, sofas, cars – these are all places we spend a lot of time, and if the fabric we are in contact with has been treated with PFAS, this represents an opportunity for exposure. People can be ...

Throwing your plastic bottles in the recycling bin may make you feel good about yourself, or ease your guilt about your ...

OBODENCE (60 mg pre-filled syringe) and XBRYK (120 mg vial) become available across Europe as of December 2025 and January 2026, respectively Marks Samsung Bioepis' 10th and 11th biosimilars ...

Bristol Myers Squibb Data at ASH 2025 Showcases Potential of Hematology Pipeline and Builds Momentum for Next Generation Portfolio ...